MBX Biosciences, Inc.

MBX Nasdaq SEC CIK 1776111
Follow MBX Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$62.4M −188.7% vs same quarter last year
EPS, diluted −$1.29 −104.8% vs same quarter last year
Operating cash flow −$34.9M −61.9% vs same quarter last year
Operating income −$66.3M −177.3% vs same quarter last year
Net income by quarter
−$15.6M
−$23.9M
−$19.4M
−$21.6M
−$22.1M
−$23.5M
−$37.1M
−$62.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$100M−$75M−$50M−$25M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$87M
FY24−$61.9M
FY23−$32.6M
FY22-
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$81.9M
FY24−$55.6M
FY23−$32.1M
FY22-